Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Insulet Corporation is a medical devices business based in the US. Insulet Corporation shares (PODD) are listed on the NASDAQ and all prices are listed in US Dollars. Insulet Corporation employs 1,900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$298.69|
|52-week range||$214.93 - $309.99|
|50-day moving average||$293.15|
|200-day moving average||$279.72|
|Wall St. target price||$291.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.47|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-0.60%|
|1 month (2021-09-22)||3.71%|
|3 months (2021-07-22)||10.03%|
|6 months (2021-04-22)||5.31%|
|1 year (2020-10-21)||23.87%|
|2 years (2019-10-21)||94.11%|
|3 years (2018-10-19)||238.69%|
|5 years (2016-10-21)||645.23%|
Valuing Insulet Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Insulet Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Insulet Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9469. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Insulet Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Insulet Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $123.7 million.
The EBITDA is a measure of a Insulet Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$995.6 million|
|Operating margin TTM||5.94%|
|Gross profit TTM||$582.3 million|
|Return on assets TTM||2.08%|
|Return on equity TTM||-5.97%|
|Market capitalisation||$20.7 billion|
TTM: trailing 12 months
There are currently 2.4 million Insulet Corporation shares held short by investors – that's known as Insulet Corporation's "short interest". This figure is 13% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Insulet Corporation shares can be evaluated.
Insulet Corporation's "short interest ratio" (SIR) is the quantity of Insulet Corporation shares currently shorted divided by the average quantity of Insulet Corporation shares traded daily (recently around 292594.7761194). Insulet Corporation's SIR currently stands at 8.04. In other words for every 100,000 Insulet Corporation shares traded daily on the market, roughly 8040 shares are currently held short.
However Insulet Corporation's short interest can also be evaluated against the total number of Insulet Corporation shares, or, against the total number of tradable Insulet Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Insulet Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Insulet Corporation shares in existence, roughly 30 shares are currently held short) or 0.0343% of the tradable shares (for every 100,000 tradable Insulet Corporation shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Insulet Corporation.
Find out more about how you can short Insulet Corporation stock.
We're not expecting Insulet Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Insulet Corporation's shares have ranged in value from as little as $214.93 up to $309.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Insulet Corporation's is 0.6799. This would suggest that Insulet Corporation's shares are less volatile than average (for this exchange).
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.